Jiangsu Recbio Technology Co., Ltd. Class H (2179) AI Stock Analysis

• Market Cap: HK$2.83B
• Dividend Yield: N/A
• Average Volume (3M): 18.70K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: N/A
• EPS Growth: -18.99%
• Country: HK
• Employees: 531
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.78
• Shares Outstanding: 316,138,700
• 10 Day Avg. Volume: 10,150
• 30 Day Avg. Volume: 18,700
• PEG Ratio: 3.04
• Price to Book (P/B): 8.14
• Price to Sales (P/S): 159.51
• P/FCF Ratio: -6.77
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -8.4
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: HK$5.50 ▼(-17.66% Downside)

The overall stock score is heavily influenced by the company's poor financial performance and valuation metrics. The financial health is precarious with declining revenue, persistent losses, and negative cash flows. Technical analysis indicates bearish momentum, with the stock trading below key moving averages. The negative P/E ratio further underscores the lack of profitability. These factors collectively result in a low overall stock score.

Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in Jiangsu, China, focusing on the research, development, and commercialization of innovative biopharmaceutical products. The company primarily operates in the healthcare sector, specializing in vaccine development and other biologics aimed at combating infectious diseases. Recbio is dedicated to leveraging advanced technologies to create effective and safe vaccines, contributing to public health and disease prevention globally.

How the Company Makes Money

Jiangsu Recbio Technology Co., Ltd. generates revenue through several key streams, primarily from the sale of vaccines and related biopharmaceutical products. The company engages in research and development (R&D) of vaccines, which, once commercialized, are sold to governments, healthcare providers, and pharmaceutical distributors. Additionally, Recbio may enter into partnerships and collaborations with larger pharmaceutical companies for co-development and distribution of its products, providing a significant source of income through licensing fees and milestone payments. Grants and funding from public health organizations and governmental bodies for vaccine development projects also contribute to the company's revenue. Furthermore, strategic partnerships with academic institutions and participation in clinical trials can enhance its product pipeline and market presence, ultimately driving sales and profitability.

Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview

Summary

Jiangsu Recbio Technology Co., Ltd. faces significant financial challenges, including declining revenue, persistent losses, and negative cash flows. High leverage and negative equity in some periods pose additional risks. Despite slight improvements in certain balance sheet metrics, the financial health remains precarious.

Income Statement

The income statement reveals a challenging financial position. Revenue has decreased from 2023 to 2024, indicating a negative growth trend. Gross Profit Margin is positive, but Net Profit Margin is significantly negative due to substantial net losses, reflecting high operational costs and inefficiencies. The company is experiencing negative EBIT and EBITDA Margins, highlighting ongoing operational challenges and lack of profitability.

Balance Sheet

The balance sheet indicates moderate risk. The company has a negative equity position in some past years, which has improved slightly but remains vulnerable. High Debt-to-Equity ratios suggest significant leverage, posing financial risk. The Return on Equity (ROE) is negative, reflecting continued losses. However, the company maintains a reasonable level of assets relative to liabilities, providing some stability.

Cash Flow

Cash flow analysis shows a concerning trend. Operating cash flow is consistently negative, reflecting cash outflows from operations. Free Cash Flow is also negative, indicating that the company is not generating sufficient cash to cover capital expenditures. The lack of positive cash flow growth suggests ongoing financial strain and limited liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	29.11M	27.00M	30.38M	5.33M	6.20M	1.46M
Gross Profit	26.20M	15.95M	22.34M	5.33M	6.20M	1.46M
EBITDA	-577.66M	-523.97M	-569.87M	-847.67M	-590.00M	-134.91M
Net Income	-653.91M	-562.39M	-571.96M	-719.20M	-657.56M	-179.40M
Balance Sheet
Total Assets	1.54B	1.94B	2.19B	2.31B	1.92B	1.05B
Cash, Cash Equivalents and Short-Term Investments	104.20M	448.31M	837.76M	1.33B	1.18B	681.71M
Total Debt	839.95M	889.10M	650.79M	282.63M	76.72M	26.13M
Total Liabilities	1.37B	1.41B	1.12B	656.53M	245.92M	2.06B
Stockholders Equity	177.63M	529.32M	1.07B	1.66B	1.67B	-1.01B
Cash Flow
Free Cash Flow	-278.63M	-636.66M	-862.18M	-888.04M	-710.79M	-241.07M
Operating Cash Flow	-184.88M	-464.82M	-638.07M	-579.54M	-472.92M	-70.34M
Investing Cash Flow	-214.61M	-279.04M	9.42M	-378.43M	68.70M	-258.59M
Financing Cash Flow	0.00	218.06M	275.27M	839.44M	1.23B	680.38M

Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.68
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Negative. The current price of 6.68 is above the 20-day moving average (MA) of 6.40, below the 50-day MA of 6.87, and below the 200-day MA of 7.77, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 20.22 is Positive, neither overbought nor oversold. The STOCH value of 27.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2179.

Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	58 Neutral	HK$1.48B	181.90	0.99%	―	9.41%	-32.69%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3681	45 Neutral	HK$2.23B	―	-55.33%	―	-100.00%	30.68%
2616	42 Neutral	HK$8.81B	-19.44	-95.84%	―	-55.64%	-158.67%
2157	40 Underperform	HK$10.72B	-51.24	-21.42%	―	240.05%	-140.09%
2179	39 Underperform	HK$2.83B	―	-129.05%	―	―	-18.99%

Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events

Jiangsu Recbio Completes Capital Verification for Domestic Shares Issuance

Jiangsu Recbio Technology Co., Ltd. has completed the payment and capital verification for its issuance of 143,112,702 domestic shares, priced at RMB5.59 each, resulting in net proceeds of RMB789,985,366.85. This successful issuance marks a significant step in the company’s financial operations, potentially enhancing its market positioning and providing additional resources for future growth initiatives.

The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.

Jiangsu Recbio Enhances Governance with New Nomination Committee

Jiangsu Recbio Technology Co., Ltd. has established a Nomination Committee to enhance its governance structure. This committee is responsible for overseeing the selection of directors and senior management, ensuring a diverse and independent board composition, and aligning the board’s skills with the company’s corporate strategies. The formation of this committee is part of the company’s efforts to comply with relevant laws and improve its corporate governance.

The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.

Jiangsu Recbio Reports Progress in Vaccine Development Amid Strategic Shift

Jiangsu Recbio Technology Co., Ltd. announced its unaudited interim results for the first half of 2025, highlighting significant progress in its vaccine development pipeline. The company is advancing its phase III clinical trials for its HPV 9-valent vaccine and shingles vaccine, with promising safety and efficacy results. However, due to low global demand, the company has decided not to pursue further clinical development of its COVID-19 vaccine, instead focusing on future respiratory combination vaccines and monitoring mRNA vaccine technology.

The most recent analyst rating on (HK:2179) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Jiangsu Recbio Technology Co., Ltd. Class H stock, see the HK:2179 Stock Forecast page.

Jiangsu Recbio Schedules Board Meeting to Review Interim Results

Jiangsu Recbio Technology Co., Ltd. has announced a board meeting scheduled for August 29, 2025, to consider and approve the unaudited interim results for the six months ending June 30, 2025, and to discuss the potential payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and strategic decisions, potentially impacting shareholder value and market perception.

Jiangsu Recbio Technology Completes Business Scope Expansion

Jiangsu Recbio Technology Co., Ltd. has completed the industrial and commercial registration for changes in its business scope and amendments to its Articles of Association. The company has revised its business scope description to include bio-based materials technology and manufacturing, which may enhance its market positioning and operational capabilities.